Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.
Venue Turmoil: Pharma Companies Oppose States’ Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC: